A research study titled, “Autoimmune Disease Diagnostics Market by product Type - Global Industry Analysis and Forecast to 2022” published by Crystal Market Research, states that the Autoimmune Disease Diagnostics Market Is Projected To Be Around $15.11 Billion By 2022.
In 2012, the global autoimmune disease diagnostics market was worth around USD 11.62 billion and is predicted to reach around USD 15.11 billion by 2022, with a compound annual growth rate (CAGR) of 2.39% during the projected period. Autoimmune disease is a hyperactive immune response of the body against the tissues and cells normally exist in the body. This disease occurs when one’s immune system attacks body cells which are working normally due to the abnormalities. The immune system mis-functioning is an outcome of the recognition failure to immune tissues, organs, and cells and developing autoantibodies aiming these cells. This disease is generally caused by environmental, genetic, or infectious factors. The occurrence of autoimmune disorder is increasing. National Institute of Health revealed that around 50 million autoimmune disease patients are in America. This disease is expected to be among the top 10 death cause in adult females under the 65 of age, which is the second uppermost source of chronic diseases. Some of the common types of autoimmune disease are rheumatoid arthritis, Crohn's disease, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, and with growing incidence of autoimmune diseases, the treatment demand is also increasing.
The global autoimmune disease diagnostics market is anticipated to demonstrate lucrative growth while maintaining a significant compound annual growth rate over the projected period of 2012 to 2022. Growing incidence of autoimmune diseases along with rising awareness among people and rising laboratories automation contributing to the diagnosis of numerous diagnostic tests concurrently to produce error-free and rapid results are the factors driving the growth of the global market. Additionally, technological innovations like the development of new biomarkers like Humira and Enbrel, and handy diagnostic PoC equipment are anticipated to boost the market growth further in the coming years. Though, factors like, insufficient funding in emerging countries, elevated cost concerned with the treatment of this disease and non-accessibility of the treatment in emerging countries combined with the appearance of optional technologies are the major restraining factors for the global market for autoimmune disease diagnostics.
The key industry participants for the global autoimmune disease diagnostics market include; Siemens Healthineers, F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Abbott Laboratories, Quest Diagnostics, SQI Diagnostics, AESKU.Diagnostics GmbH & Co. KG, EUROIMMUN AG, INOVA Diagnostics, Inc., bioMerieux SA, Crescendo Bioscience, Inc., Hemagen Diagnostics, Inc., and Bio-Rad Laboratories, Inc. According to the product type, the market is classified as; Apheresis machine and Disposable Apheresis kits. On the basis of the procedure, the global market industry is divided into; Plasmapheresis, Plateletpheresis, LDL-apheresis, Leukapheresis, Erythrocytapheresis, Photopheresis and Other Equipment. By application, the market is split as; Hematology, Renal Diseases, Neurology and Other Applications. Depending on the technology used, the market is split into; Centrifugation and Membrane Separation. Geographically, the global autoimmune disease diagnostics market is segmented into regions which are; Europe (Germany, Spain, Italy, France, UK and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and Rest of Asia Pacific), North America (the United States, Mexico and Canada)and Rest of the World (Brazil, Saudi Arabia, South Africa, United Arab Emirates and Others).
Browse full research report with TOC on “Autoimmune Disease Diagnostics Market By Type - Global Industry Analysis And Forecast To 2022” at:
Key findings of the autoimmune disease diagnostics market